Editorial Comment from Dr. Kato to Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Int J Urol
; 30(10): 874-875, 2023 Oct.
Article
en En
| MEDLINE
| ID: mdl-37563925
Texto completo:
1
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Int J Urol
Asunto de la revista:
UROLOGIA
Año:
2023
Tipo del documento:
Article